Search

Your search keyword '"Sunao Tokumaru"' showing total 2 results
Start Over Author "Sunao Tokumaru" Publisher elsevier
2 results on '"Sunao Tokumaru"'

1. Definitive particle therapy using protons or carbon ions for dedifferentiated liposarcoma

Author

Hikaru Kubota, Yusuke Demizu, Kazuma Iwashita, Nobuyoshi Fukumitsu, Daiki Takahashi, SungChul Park, Shintaro Tsuruoka, Yoshiro Matsuo, Kazuki Terashima, Sunao Tokumaru, Tomoaki Okimoto, and Toshinori Soejima

Subjects
Liposarcoma, Sarcoma, Radiotherapy, Proton therapy, Heavy ion therapy, Carbon, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Particle therapy is effective for the treatment of soft tissue sarcomas. However, the clinical outcomes of definitive particle therapy, particularly for dedifferentiated liposarcoma (DDLS), remain unknown. Purpose: To analyze the treatment outcomes of proton and carbon ion particle therapies for DDLS. Methods: We retrospectively included patients with DDLS who were treated with particle therapy between 2008 and 2022. The local control (LC), progression-free survival (PFS), and overall survival (OS) rates were evaluated. Results: Fifty-seven patients were included in this analysis. The median patient age was 68 years (range, 36–91 years). The most common tumor site was the retroperitoneum (n = 37), with a median gross tumor volume (GTV) of 181 cm3. Twenty-nine patients received proton therapy, and 28 patients received carbon ion therapy. The most common fractionation dose was 70.4 Gy (relative biological effectiveness) in 32 fractions (72.7 Gy equivalent dose in 2 Gy fractions [EQD2]). The median follow-up time was 33 months (range, 1–128 months). The 3-year LC, PFS, and OS rates were 73.1 %, 44.6 %, and 70.6 %, respectively. Patients who received a higher prescribed dose (≥72.7 Gy EQD2) showed significantly better LC (p = 0.04) than did those who received a lower prescribed dose. Moreover, those with a larger GTV (≥181 cm3) had significantly worse OS (p = 0.04) than did those with a smaller GTV. Late adverse events occurred in five (9 %) patients. Conclusions: Particle therapy using protons or carbon ions for the treatment of DDLS is safe and provides good OS and LC. However, further studies with longer follow-up periods and larger cohorts are warranted.

Published
2024
Full Text
View/download PDF

2. Proton Beam Therapy for Histologically or Clinically Diagnosed Stage I Non-Small Cell Lung Cancer (NSCLC) : The First Nationwide Retrospective Study in Japan

Author

Shigeyuki Murayama, Kayoko Ohnishi, Takashi Ogino, Tetsuo Akimoto, Hitoshi Wada, Yoshitaka Sato, Jun-etsu Mizoe, Tomoaki Okimoto, Hideyuki Harada, Yuta Sekino, Hitoshi Ishikawa, Naoki Nakamura, Yasuhito Kikuchi, Hideyuki Sakurai, Hiromitsu Iwata, Sunao Tokumaru, Takeshi Arimura, and Hiroyasu Tamamura

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Stage I Non-Small Cell Lung Cancer, Kaplan-Meier Estimate, Gastroenterology, Effective dose (radiation), 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Japan, Carcinoma, Non-Small-Cell Lung, Internal medicine, Proton Therapy, medicine, Carcinoma, Humans, Radiology, Nuclear Medicine and imaging, Progression-free survival, Adverse effect, Survival rate, Aged, Neoplasm Staging, Retrospective Studies, Pneumonitis, Aged, 80 and over, Radiation, business.industry, Incidence, Radiotherapy Dosage, Retrospective cohort study, Middle Aged, medicine.disease, Progression-Free Survival, Radiation Pneumonitis, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Female, Radiodermatitis, business, Relative Biological Effectiveness, Follow-Up Studies
Abstract

Purpose To investigate the efficacy and safety of proton beam therapy (PBT) for the treatment of stage I non-small cell lung cancer (NSCLC). Methods and Materials Six hundred sixty-nine patients with 682 tumors histologically or clinically diagnosed stage I NSCLC according to the seventh edition of Union for International Cancer Control who received passive-scattering PBT from April 2004 and December 2013 in Japan were retrospectively reviewed to analyze survival, local control, and toxicities. Results Of 669 patients, 486 (72.6%) were men, with a median age of 76 years (range, 42-94 years). NSCLC was histologically confirmed in 440 patients (65.7%). Clinical T stages included T1a (n = 265; 38.9%), T1b (n = 216; 31.7%), and T2a (n = 201; 29.4%). The total irradiation doses of PBT ranged from 74.4 to 131.3 biological effective dose GyE (median, 109.6 biological effective dose GyE). The median follow-up period was 38.2 months (range, 0.6-154.5 months) for all patients. The 3-year overall survival and progression-free survival rates for all patients were 79.5% and 64.1%, respectively. For patients with stage IA tumors, the 3-year overall survival and progression-free survival rates were 82.8% and 70.6%, respectively, and the corresponding rates for patients with stage IB tumors were 70.8% and 47.3%, respectively. The 3-year local progression-free rates for all, stage IA, and stage IB patients were 89.8%, 93.5%, and 79.4%, respectively. The incidence of grade 2, 3, 4, and 5 pneumonitis was 9.8%, 1.0%, 0%, and 0.7%, respectively. The incidence of grade ≥3 dermatitis was 0.4%. No grade 4 or severe adverse events, other than pneumonitis, were observed. Conclusions PBT appears to yield acceptable survival rates, with a low rate of toxicities.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results